Breaking news: CDC announces shortage of antimalarial drug primaquine
The Centers for Disease Control and Prevention warned this week that the antimalarial drug primaquine is not available until September, 2011.
The Centers for Disease Control and Prevention (CDC) warned this week that the antimalarial drug primaquine is not available until September, 2011.
Primaquine’s manufacturer, Sanofi-Aventis, reported the drug shortage to the CDC. Sanofi-Aventis representatives did not respond to Formulary’s request for comment.
“Primaquine is the only drug that can be used to eliminate hypnozoites, the dormant forms of malaria parasites,” the CDC said in a statement. Still, healthcare providers may choose to maintain persons at risk of relapse on weekly chloroquine prophylaxis until primaquine is available again.
“Additionally, during the shortage, primaquine should not be prescribed for primary chemoprophylaxis,” the CDC stated.
Besides primaquine and chloroquine, medications recommended to treat malaria include atovaquone/proguanil, doxyclycline, and mefloquine.
Nearly 82 million malaria cases were reported worldwide in 2009, with the highest prevalence in Uganda, Kenya, and the Democratic Republic of Congo.
FDA Approves Subcutaneous Tecentriq to Treat Multiple Cancers
September 13th 2024Tecentriq Hybreza can be administered over seven minutes, compared with 30 to 60 minutes for IV infusion of Tecentriq. There is no word yet on when Tecentriq Hybreza will be available or what the price will be.
Read More
FDA Warns of Liver Injury with Veozah for Hot Flashes
September 12th 2024The FDA has identified a probable case of serious drug induced liver injury that occurred in a woman in the United States who had received Veozah. The agency is requiring additional liver blood testing after starting therapy.
Read More
